Hepatitis C Virus Prevention and Treatment Prioritisation – ethical economic and evidential dimensions of early rather than delayed treatment for people who inject drugs

摘要

New hepatitis C virus (HCV) treatments with very high cure rates can reduce the burden of liver disease in the population and could reduce HCV transmission. There are no ethical grounds for denying these treatments to people with severe or moderate liver disease who inject drugs (PWID). The cost-effectiveness of providing HCV treatment for PWID who have early stages of liver disease remains to be demonstrated.